The present invention is concerned with treatment or prevention of progression of myocardial infarction or adverse cardiac remodeling related conditions such as remote myocardial fibrosis by administering a binding member such as, a neutralizing antibody, binding to fibronectin-EDA, in particular the EDA domain of fibronectin-EDA to a subject in need thereof.